Geneva [Switzerland], May 5 (ANI/PRNewswire): The first US patient has been enrolled in the SELUTION4SFA Sirolimus DEB study by Dr Arthur Lee at the Cardiac & Vascular Institute in Florida. This study evaluates SELUTION SLR in the treatment of occlusive disease of the superficial femoral artery (SFA) and proximal popliteal artery (PPA) and has been designed to support FDA approval. It follows Investigational Device Exemption (IDE) approval in the US in August 2022. SELUTION SLR is the first and only limus release drug-eluting balloon (DEB) to receive FDA IDE approval for SFA and PPA indica...